Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2016', provides an overview of the Microscopic Polyangiitis (MPA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA) - The report reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Microscopic Polyangiitis (MPA) therapeutics and enlists all their major and minor projects - The report assesses Microscopic Polyangiitis (MPA) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA) Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Microscopic Polyangiitis (MPA) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Microscopic Polyangiitis (MPA) Overview 6 Therapeutics Development 7 Pipeline Products for Microscopic Polyangiitis (MPA) - Overview 7 Microscopic Polyangiitis (MPA) - Therapeutics under Development by Companies 8 Microscopic Polyangiitis (MPA) - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Microscopic Polyangiitis (MPA) - Products under Development by Companies 12 Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development 13 ChemoCentryx, Inc. 13 Coherus BioSciences, Inc. 14 Epirus Biopharmaceuticals, Inc. 15 GlaxoSmithKline Plc 16 Panacea Biotec Limited 17 Sandoz International GmbH 18 Teijin Pharma Limited 19 Microscopic Polyangiitis (MPA) - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 belimumab - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 CCX-168 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 immune globulin (human) - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 rituximab biosimilar - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 rituximab biosimilar - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 rituximab biosimilar - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 rituximab biosimilar - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Microscopic Polyangiitis (MPA) - Recent Pipeline Updates 40 Microscopic Polyangiitis (MPA) - Dormant Projects 47 Microscopic Polyangiitis (MPA) - Product Development Milestones 48 Featured News & Press Releases 48 Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 48 Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50
List of Tables
Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx, Inc., H1 2016 13 Microscopic Polyangiitis (MPA) - Pipeline by Coherus BioSciences, Inc., H1 2016 14 Microscopic Polyangiitis (MPA) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016 15 Microscopic Polyangiitis (MPA) - Pipeline by GlaxoSmithKline Plc, H1 2016 16 Microscopic Polyangiitis (MPA) - Pipeline by Panacea Biotec Limited, H1 2016 17 Microscopic Polyangiitis (MPA) - Pipeline by Sandoz International GmbH, H1 2016 18 Microscopic Polyangiitis (MPA) - Pipeline by Teijin Pharma Limited, H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Microscopic Polyangiitis (MPA) Therapeutics - Recent Pipeline Updates, H1 2016 40 Microscopic Polyangiitis (MPA) - Dormant Projects, H1 2016 47
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.